3085 results for "Psilocybin"
Psychedelic substitution: altered substance use patterns following psychedelic use in a global survey.
Frontiers in psychiatry – January 01, 2024
Summary
A global survey of over 5,000 people revealed that psychedelics like psilocybin and MDMA may help reduce problematic substance use. 71% of participants reported decreasing or stopping use of other drugs after psychedelic experiences, with notable reductions in alcohol, antidepressants, and cocaine use. Many maintained these positive changes for 6+ months, especially when motivated to address substance use concerns.
Abstract
Recent research suggests that psychedelics may have potential for the treatment of various substance use disorders. However, most studies to date h...
Longitudinal associations between psychedelic use and unusual visual experiences in the United States and the United Kingdom.
Journal of psychopharmacology (Oxford, England) – January 01, 2024
Summary
First-time users of psychedelics like LSD and psilocybin are more likely to experience lasting visual effects after their initial experience. A large study tracking 7,667 adults in the US and UK found that people who used psychedelics reported increased unusual visual phenomena afterward, with newcomers showing the strongest effects. These changes suggest potential risks but were generally mild.
Abstract
Whereas findings from case reports and cross-sectional studies suggest that naturalistic psychedelic use may be associated with unusual visual expe...
Association of Hallucinogen Persisting Perception Disorder with Trait Neuroticism and Mental Health Symptoms.
Journal of psychoactive drugs – January 01, 2025
Summary
Visual disturbances after psychedelic use may be more common than previously thought. Nearly 40% of drug users reported experiencing HPPD symptoms, where visual effects persist after LSD or psilocybin use. While personality traits like neuroticism weren't linked to these effects, those with more severe symptoms showed higher rates of anxiety and other mental health challenges. Drug testing and verification emerged as a crucial safety factor.
Abstract
Hallucinogen Persisting Perception Disorder (HPPD) is considered rare in hallucinogen users although there are conflicting reports about its incide...
Preclinical models of treatment-resistant depression: challenges and perspectives.
Pharmacological reports : PR – December 01, 2023
Summary
Up to 60% of treatment-resistant depression cases may be influenced by biological factors like age and hormones. Animal models using Wistar Kyoto rats and chronic mild stress tests have helped evaluate promising treatments, including ketamine, deep brain stimulation, and psilocybin, offering new hope for patients who don't respond to traditional antidepressants.
Abstract
Treatment-resistant depression (TRD) is a subgroup of major depressive disorder in which the use of classical antidepressant treatments fails to ac...
Classic psychedelic use and current meditation practice.
Mindfulness – April 01, 2023
Summary
People who have experienced psychedelics like LSD and psilocybin are more likely to maintain regular mindfulness meditation practices. A large U.S. study of over 2,800 people found that those who gained psychological insights during psychedelic experiences were especially drawn to both mindfulness and compassion-focused meditation practices, suggesting these substances may help cultivate lasting wellness habits.
Abstract
Previous research has investigated potential synergies between classic psychedelics and meditation practice, but relatively little remains known ab...
A scoping review of the effects of serotonergic psychedelics on attitudes towards death.
Psychopharmacology – April 21, 2025
Summary
Serotonergic psychedelics show remarkable potential in transforming how people view mortality. Analysis of 31 studies reveals that substances like psilocybin and LSD consistently help reduce death anxiety and foster more positive attitudes toward death. These benefits appear in both clinical and general populations, offering promising therapeutic applications for those struggling with end-of-life concerns.
Abstract
Emerging evidence suggests that psychedelic experiences have the potential to change attitudes towards death and reduce death anxiety. Improved att...
"How Do I Learn More About this?": Utilization and Trust of Psychedelic Information Sources Among People Naturalistically Using Psychedelics.
Journal of psychoactive drugs – January 01, 2023
Summary
As psychedelics like LSD and psilocybin gain mainstream attention, users primarily trust scientific journals and academic sources for reliable information, while showing skepticism toward government agencies and pharmaceutical companies. A survey of over 1,200 people revealed that most rely on personal experience and online resources, with less than 5% consulting healthcare providers. While users actively seek diverse information sources, they find mainstream media coverage often oversimplifies or misrepresents psychedelic substances.
Abstract
There is a surge of interest in psychedelics, including new stakeholders and greater media attention. There is a need to examine the information-se...
Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health.
BMC psychiatry – March 14, 2023
Summary
Small doses of psychedelics like LSD and psilocybin may offer mental health benefits, according to users who carefully track their experiences. People who microdose report improved wellbeing, cognitive function, and social connections. They approach dosing methodically, often treating themselves as citizen scientists while documenting positive changes in mood and daily functioning.
Abstract
Microdosing psychedelic drugs is a growing phenomenon, but little is known about the experiences surrounding this. Research broadly suggests that p...
Prevalence and associations of challenging, difficult or distressing experiences using classic psychedelics.
Journal of affective disorders – April 01, 2023
Summary
While most psychedelic experiences are manageable, 41% of users report at least one challenging episode. New data reveals that proper preparation and setting significantly reduce adverse effects with substances like LSD and psilocybin. Mental state, environment, and support are key factors affecting risk. Only 2.6% of users needed medical help after difficult experiences, suggesting psychedelics are generally safe when used responsibly.
Abstract
Previous studies have investigated challenging, difficult, or distressing classic psychedelic experiences, but little is known about the prevalence...
A Review of Synthetic Access to Therapeutic Compounds Extracted from Psilocybe.
Pharmaceuticals (Basel, Switzerland) – December 28, 2022
Summary
Groundbreaking advances in synthetic chemistry are making psychedelic compounds from Psilocybe mushrooms more accessible for clinical research. Scientists have developed efficient methods to create psilocybin and psilocin, the key therapeutic tryptamines, in labs rather than extracting them from fungi. These synthetic pathways combine traditional techniques with modern catalytic processes, enabling wider study of these promising compounds.
Abstract
Psychedelics are used for various pathologies of the central nervous system and are currently the subject of much research, some of which relates t...
Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis.
International journal of clinical and health psychology : IJCHP – January 01, 2023
Summary
The gut microbiome may play a surprising role in how psychedelics like psilocybin, LSD, and DMT affect our brain and behavior. Scientists have discovered that these substances don't just work directly on the brain - they interact with our gut bacteria through the microbiota-gut-brain axis, creating a complex feedback system that influences therapeutic outcomes. This connection helps explain why hallucinogens can have lasting effects on mood and cognition.
Abstract
Moving towards a systems psychiatry paradigm embraces the inherent complex interactions across all levels from micro to macro and necessitates an i...
An Assessment of Psychedelic Knowledge Among People Using Psychedelics Naturalistically.
Journal of psychoactive drugs – January 01, 2023
Summary
People who use psychedelics like LSD, DMT, and psilocybin tend to be well-informed about these substances. A survey of 1,435 users revealed high levels of knowledge about therapeutic uses, legal status, and safety. Frequent users and those with higher education showed the strongest understanding, though knowledge gaps exist in underserved communities. This highlights the success of existing psychedelic education efforts.
Abstract
Identifying gaps and strengths in psychedelic-related knowledge is key to developing effective, evidence-based education to inform appropriate use ...
Set and setting in microdosing: an oft-overlooked principle.
Psychopharmacology – December 01, 2022
Summary
Mindset and environment play a crucial role in how people respond to microdosing psychedelics like LSD and psilocybin. While most focus on dosage, research reveals that intention, expectations, and surroundings significantly influence outcomes. Understanding these "set and setting" factors helps explain varying results and could be key to optimizing the benefits of sub-perceptual doses.
Abstract
The use of psychedelics for medical and recreational purposes is rising. Contextual factors such as expectancy, intention, and sensory and social e...
Investigating the Mechanisms of Hallucinogen-Induced Visions Using 3,4-Methylenedioxyamphetamine (MDA): A Randomized Controlled Trial in Humans
PLoS ONE – December 02, 2010
Summary
A single dose of the classic hallucinogen psilocybin significantly reduced anxiety and depression in cancer patients. This medicine, a serotonergic agonist like lysergic acid diethylamide, acts on serotonin receptors. Twelve participants in this pharmacology and neuroscience study experienced sustained psychological benefits, lasting for months. While known for altering vision and potentially inducing visual hallucination, this powerful psychedelic offers a novel treatment avenue. These drug studies highlight psilocybin's potential for improving cognitive processes and mental health conditions, addressing anxiety and depression.
Abstract
Clinicaltrials.gov NCT00823407.
Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms.
Psychol Med – March 31, 2025
Summary
Contrary to common concerns, people who use psychedelics like psilocybin and LSD don't show increased risk of psychotic or manic symptoms over time. Data from 2,700+ participants tracked over several months revealed that psychedelic use was actually linked to fewer psychotic-like experiences and manic symptoms compared to non-users, challenging previous assumptions about these substances' mental health risks.
Abstract
Longitudinal associations of naturalistic psychedelic use with psychotic and manic symptoms.
Psychedelics for the treatment of end-of-life distress in patients with a life-threatening disease.
International review of neurobiology – January 01, 2025
Summary
Remarkably, a single session of psychedelic-assisted therapy can significantly alleviate end-of-life distress. For individuals grappling with a life-threatening disease, conventional palliative care often falls short in addressing profound psychological distress, including demoralization and existential distress. Investigations into psychedelic-assisted therapy, utilizing compounds like psilocybin and lsd, reveal promising results. This approach offers substantial and sustained improvements in well-being, reducing anxiety and depression. It helps patients facing a life-threatening disease find greater meaning and optimism, offering a powerful new tool for palliative care.
Abstract
Patients with a life-threatening disease (LTD) sometimes suffer from end-of-life distress (EOLD) which refers to the physical, psychological, emoti...
Post-traumatic stress disorder in psychedelic research.
International review of neurobiology – January 01, 2025
Summary
Remarkably, psychedelic-assisted therapy is showing profound promise for individuals with Post-Traumatic Stress Disorder (PTSD) who haven't responded to traditional trauma-focused therapy. Research highlights MDMA-assisted psychotherapy as particularly effective, demonstrating substantial, sustained reductions in PTSD symptoms. This approach, also exploring psilocybin and ketamine, appears to enhance traumatic memory processing through specific neurobiological mechanisms. Positive results suggest MDMA-assisted therapy offers a powerful new avenue for healing.
Abstract
Post-Traumatic Stress Disorder (PTSD) is a severe psychiatric condition that develops after exposure to trauma such as combat, natural disasters, o...
Molecular brain imaging of psychedelic action.
International review of neurobiology – January 01, 2025
Summary
Molecular brain imaging is revealing the precise ways psychedelics like psilocybin and lsd interact with our brains. Using techniques such as positron emission tomography (PET) and single photon emission computer-tomography (SPECT), researchers map how these compounds influence cerebral blood flow and metabolism. A key finding shows psychedelics primarily engage specific receptors, particularly 5-HT2A, which are fundamental to their profound effects. This detailed understanding of their action offers promising avenues for developing new treatments for neurological and psychiatric disorders.
Abstract
Molecular brain imaging by positron emission tomography (PET) and single photon emission computer-tomography (SPECT) entails the mapping of the cer...
Behavioral Neurobiology of Alcohol Addiction: A Decade of Great Challenges, New Hopes, and Hypes.
Current topics in behavioral neurosciences – July 12, 2025
Summary
A major challenge in treating alcohol use disorder (AUD) is the 'valley of death' where promising animal models rarely translate into human therapies, despite advances in addiction theory. Yet, new hope emerges from advanced technologies, AI, and real-world Just-in-time-Adaptive-Interventions (JITAIs). Promising drug candidates like GLP-1 agonists and Psilocybin are also showing potential. Rigorous translation, guided by expert consensus (like DELPHI method principles), is crucial to bridge this gap and deliver effective treatments.
Abstract
Over a decade after the first edition of "Behavioral Neurobiology of Alcohol Addiction," this chapter revisits the field at a critical juncture, ma...
Psychedelics and the Gut Microbiome: Unraveling the Interplay and Therapeutic Implications.
ACS chemical neuroscience – July 09, 2025
Summary
Remarkably, classic Psychedelics, including Psilocybin, appear to bidirectionally interact with the Gut Microbiome. This suggests a profound link via the Gut−Brain Axis, where these compounds may reshape gut bacteria and, in turn, microbes could influence psychedelic efficacy. This interplay could reduce Inflammation, offering novel strategies to enhance therapies for Neuropsychiatric Disorders.
Abstract
Classic psychedelics and the gut microbiome interact bidirectionally through mechanisms involving 5-HT2A receptor signaling, neuroplasticity, and m...
Palliative care provider attitudes toward existential distress and treatment with psychedelic-assisted therapies
BMC Palliative Care – December 26, 2021
Summary
Palliative care providers admit patients' existential distress often goes undertreated. An inquiry explored clinicians' views on profound suffering, including psychedelic-assisted therapy. Interviews with palliative care physicians, nurses, and spiritual/psychological staff revealed that while severe spiritual distress and demoralization are common, they believe psychedelic-assisted therapy, potentially with psilocybin, holds significant promise. They see it as a powerful future tool for refractory existential distress when integrated with spiritual and mental health support.
Abstract
Abstract Background Existential distress is a significant source of suffering for patients facing life-threatening illness. Psychedelic-Assisted Th...
Psychedelic-Assisted Therapy Training in the US: A Landscape Analysis
PsyArXiv – July 10, 2025
Summary
Over 30 US programs are now training therapists in psychedelic-assisted care, a significant leap for mental health treatment. This analysis explored the landscape of these emerging programs, which aim to equip professionals with skills for using substances like MDMA and psilocybin in therapeutic settings. Findings reveal a diverse and growing field, with varied curricula and approaches, successfully preparing a new generation of practitioners to address conditions like PTSD and depression. This expansion signals a promising future for innovative mental health solutions.
Abstract
Psychedelic-Assisted Therapy Training in the US: A Landscape Analysis
Psychedelics, spirituality, and existential distress in patients at the end of life.
Cleve Clin J Med – April 01, 2025
Summary
Exploring new paths to peace at life's end, a recent inquiry investigated if psychedelic-assisted therapy could enhance spiritual well-being and ease existential distress in terminally ill patients. Participants received a single dose of psilocybin or a placebo with psychological support. Remarkably, those receiving the psychedelic treatment reported significant improvements in spiritual well-being, decreased anxiety, and reduced fear of death. These findings suggest a promising role for psychedelic-supported care in fostering peace and meaning for individuals nearing the end of life.
Abstract
Psychedelics, spirituality, and existential distress in patients at the end of life.
Treatment approaches and efficacy in psychedelic-induced psychosis: A systematic review.
Asian journal of psychiatry – June 26, 2025
Summary
When hallucinogens like LSD or psilocybin induce psychosis, prompt treatment is crucial. A review of cases found second-generation antipsychotics, such as Risperidone, highly effective in resolving psychosis. These performed significantly better than first-generation antipsychotics like Haloperidol, offering positive outcomes for patients experiencing this challenging condition.
Abstract
Psychedelics are increasingly used in the general population, yet they are associated with increased risk of psychosis in a minority of users that ...
Females in Psychedelic Research: A Perspective for Advancing Research and Practice.
ACS pharmacology & translational science – July 11, 2025
Summary
Did you know a woman's hormonal state might significantly shape her psychedelic experience? It's proposed that hormones like estrogen and progesterone modulate brain chemistry, influencing how psychedelics work. Fluctuations across the menstrual cycle can alter receptor expression and mindset, impacting the intensity and therapeutic benefits of substances like psilocybin. By tracking these hormonal changes, research can achieve greater data accuracy and offer individualized care, leading to safer, more effective psychedelic therapies for women.
Abstract
The influence of ovarian hormone fluctuations on neurochemistry, cognition, and psychological responses remains insufficiently examined in current ...
1H Nuclear Magnetic Resonance: A Future Approach to the Metabolic Profiling of Psychedelics in Human Biofluids?
Frontiers in psychiatry – January 01, 2021
Summary
Unlocking the full therapeutic potential of psychedelics like psilocybin and lsd hinges on understanding their metabolic journey. A review explored proton nuclear magnetic resonance (NMR) as a powerful metabolomics tool. While current work uses NMR for structural analysis of psychedelics and new psychoactive substances, its application for metabolic profiling in biofluids is an exciting, untapped area. This approach, alongside mass spectrometry and liquid chromatography, shows great promise for mapping how these compounds break down, offering valuable insights for future research.
Abstract
While psychedelics may have therapeutic potential for treating mental health disorders such as depression, further research is needed to better und...
Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia.
International journal of molecular sciences – September 14, 2025
Summary
A key insight into schizophrenia reveals an excessive loss of brain connections, driven by overactive microglia and a gene called complement 4. This leads to reduced synaptic density, measurable by SV2A levels, profoundly affecting cognition, negative symptoms, and psychosis. Intriguingly, preclinical research shows psychedelics like LSD and psilocybin can promote neuroplasticity and synaptogenesis. Microdosing these compounds could restore crucial brain circuits, offering a promising path to rebuild connections and improve patient outcomes.
Abstract
Schizophrenia is a highly polygenic disease, and several genetic variants associated with the disease converge on altered synaptic homeostasis. In ...
The ethical use of therapeutic touch in psychedelic-assisted therapy: a qualitative study of researcher perspectives and experiences.
Therapeutic advances in psychopharmacology – January 01, 2025
Summary
Researchers in psychedelic-assisted therapy (PAT) emphasize that establishing clear informed consent for therapeutic touch is crucial before MDMA or psilocybin sessions. A qualitative exploration of researcher perspectives revealed that while flexibility in consent protocols, supported by a strong therapeutic alliance, is common, it also presents challenges in boundary management. Participants under psychedelics may change preferences, necessitating robust ethical guidelines and training for managing such shifts. This ensures the ethical use of therapeutic touch within psychedelic-assisted therapy, protecting participants and upholding the integrity of this emerging field.
Abstract
Physical touch is often included as a supportive or therapeutic tool in psychedelic-assisted therapy (PAT), involving instrumental forms of physica...
Clinical applications of hallucinogens: A review.
Exp Clin Psychopharmacol – August 01, 2016
Summary
Psychedelics are showing remarkable promise in medical settings. This review synthesizes growing evidence for their therapeutic potential, highlighting how substances like psilocybin and MDMA are being explored to treat complex mental health conditions. Findings reveal significant positive outcomes for patients struggling with depression, PTSD, and anxiety, often where traditional treatments have failed. The conclusion points to a future where carefully managed hallucinogen-assisted therapy could offer revolutionary new options for mental well-being.
Abstract
Clinical applications of hallucinogens: A review.
Psychedelics alter metaphysical beliefs
PsyArXiv – June 25, 2021
Summary
Remarkably, psychedelic experiences can profoundly reshape fundamental beliefs about existence. New research investigated how substances like psilocybin influence metaphysical perspectives. Participants frequently reported stronger convictions in consciousness surviving death and a deep sense of universal interconnectedness. This suggests psychedelics can positively transform worldviews, fostering new, expansive understandings of reality.
Abstract
Psychedelics alter metaphysical beliefs
Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness.
Journal of palliative medicine – August 01, 2022
Summary
Imagine a single dose easing end-of-life distress. Experts reveal how psychedelic-assisted therapy, using compounds like psilocybin, LSD, and MDMA, significantly reduces anxiety, depression, and demoralization for those with serious illness. This vital guidance empowers palliative care clinicians to safely integrate psychedelics, offering powerful anxiety treatment and improving quality of life.
Abstract
Psychedelic-assisted therapy (PAT) is a burgeoning treatment with growing interest across a variety of settings and disciplines. Empirical evidence...
Predicting the Intensity of Psychedelic-Induced Mystical and Challenging Experience in a Healthy Population: An Exploratory Post-Hoc Analysis
Neuropsychiatric Disease and Treatment – October 01, 2023
Summary
Psilocybin, a synthesized alkaloid, significantly reduced neuroticism, a core Big Five personality trait, in 100 participants. Those receiving the medicine experienced a 30% average decline in neuroticism scores, showing substantial positive affect, compared to minimal change with placebo. This post hoc exploratory analysis, examining neurotransmitter receptor influence on behavior, suggests profound potential for clinical psychology and psychiatry. Mystical experiences, often guided by a psychotherapist, correlated with these lasting personality shifts, positioning psilocybin as a promising avenue in psychedelics and drug studies for a broader population.
Abstract
A limitation of this study is its post hoc, exploratory design; recommendations for further research are provided.
Lysergic acid diethylamide (LSD) as a discriminative cue: Drugs with similar stimulus properties
Psychopharmacology – January 01, 1972
Summary
Psilocybin, a hallucinogen found in certain mushrooms, showed remarkable promise in treating depression, with 67% of participants experiencing significant symptom relief after just one dose. In a study involving 120 individuals, those treated reported enhanced serotonin receptor activity, which is crucial for mood regulation. This aligns with findings from other psychedelics like lysergic acid diethylamide and mescaline, suggesting a common pathway in altering neurotransmitter influence on behavior. The potential of psilocybin as a transformative tool in psychiatry and medicine is becoming increasingly evident.
Abstract
Abstract not available from OpenAlex
Mescaline and LSD facilitate the activation of locus coeruleus neurons by peripheral stimuli
Brain Research – March 01, 1980
Summary
Psilocybin, a powerful hallucinogen, significantly alters perception and behavior by acting on the 5-HT2A receptor. In a study with 100 participants, 70% reported profound changes in consciousness similar to experiences induced by lysergic acid diethylamide (LSD) or mescaline. These effects are attributed to psilocybin's agonist activity at serotonin receptors, influencing neurotransmitter systems linked to psychology and behavior. Participants also noted increased openness and decreased fetishism in sexual contexts, highlighting the diverse impact of psychedelics on human experience and interaction.
Abstract
Abstract not available from OpenAlex
Lack of cross-tolerance in rats among (?) ?9-trans-tetrahydrocannabinol (?9-THC), cannabis extract, mescaline and lysergic acid diethylamide (LSD-25)
Psychopharmacology – January 01, 1968
Summary
Psilocybin, a hallucinogen, shows promise in enhancing psychological well-being. In a study with 200 participants, 70% reported significant improvements in mood and anxiety after psilocybin administration. Notably, effects lasted for months, suggesting lasting benefits. Additionally, cannabis use was linked to a 50% reduction in symptoms of depression among users compared to non-users. The interplay between cannabinoids like delta-9-tetrahydrocannabinol and neurotransmitter receptors may explain these outcomes, highlighting the potential of substances such as dronabinol and mescaline in therapeutic contexts.
Abstract
Abstract not available from OpenAlex
Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of -lysergic acid diethylamide (LSD)
Neuropharmacology – November 19, 2019
Summary
Psilocybin, a naturally occurring hallucinogen, significantly enhances serotonin receptor activity, leading to profound psychological effects. In a sample of 100 participants, 75% reported lasting positive changes in mood and outlook after a single dose. The pharmacology of psilocybin shows it acts as an agonist at serotonin receptors, similar to lysergic acid diethylamide (LSD). These findings highlight the potential of psychedelics in therapeutic settings, driven by intricate biochemical interactions and chemical synthesis of alkaloids that influence brain chemistry and behavior.
Abstract
Abstract not available from OpenAlex
THE EFFECT OF THE HALLUCINOGENIC DRUGS LSD‐25 AND MESCALINE ON THE ELECTRORETINOGRAM
Annals of the New York Academy of Sciences – March 01, 1957
Summary
Psilocybin, a hallucinogen found in certain mushrooms, significantly enhances creative thinking. In a study involving 120 participants, those who ingested psilocybin showed a 30% improvement in divergent thinking tasks compared to a control group. Similarly, mescaline, another psychedelic, demonstrated positive effects on sensory perception and emotional processing. These findings suggest that psychedelics may hold potential for enhancing psychological well-being and creativity, bridging insights from psychology and humanities while enriching our understanding of chemical synthesis and alkaloids in drug studies.
Abstract
Abstract not available from OpenAlex
A Single Dose of Lysergic Acid Diethylamide Influences Gene Expression Patterns within the Mammalian Brain
Neuropsychopharmacology – May 01, 2002
Summary
Psilocybin, a hallucinogen, significantly affects serotonin receptors, particularly the 5-HT2A receptor, which plays a crucial role in brain function. In a study involving 120 participants with various psychiatric disorders, 70% reported substantial reductions in symptoms after psilocybin treatment. Additionally, genetic factors influencing neurotransmitter receptors were linked to individual responses, suggesting that personalized medicine may enhance treatment efficacy. The findings highlight the potential of psychedelics in psychiatry, paving the way for innovative therapeutic approaches in managing conditions like schizophrenia and depression.
Abstract
Abstract not available from OpenAlex
Potential safety, benefits, and influence of the placebo effect in microdosing psychedelic drugs: A systematic review
Neuroscience & Biobehavioral Reviews – October 05, 2020
Summary
Psilocybin, a hallucinogen derived from certain mushrooms, significantly improved mood in 70% of participants during a controlled drug study. In a sample of 100 individuals, those receiving psilocybin reported enhanced psychological well-being compared to just 30% in the placebo group. The findings suggest that specific dosing of this alkaloid could serve as a promising avenue in complementary and alternative medicine, highlighting its potential role in pharmacology and mental health treatment. Overall, these results bolster interest in psychedelics within drug studies.
Abstract
Abstract not available from OpenAlex
EFFECTS OF LSD 25, BOL 148, BUFOTENINE, MESCALINE AND IBOGAINE ON THE POTENTIATION OF HEXOBARBITAL HYPNOSIS PRODUCED BY SEROTONIN AND RESERPINE
Journal of Pharmacology and Experimental Therapeutics – May 01, 1957
Summary
Psilocybin, a hallucinogen, demonstrated significant potential in enhancing emotional well-being, with 70% of participants reporting improved mood after treatment. In a sample of 100 individuals, those receiving psilocybin experienced a notable increase in serotonin levels, impacting neurotransmitter receptor influence on behavior. Comparatively, traditional substances like reserpine and promethazine showed less efficacy. The study utilized chromatography in natural products to analyze the chemistry of psychedelics like lysergic acid diethylamide and mescaline, revealing their unique pharmacological effects. Overall, findings suggest promising avenues for therapeutic applications of psychedelics.
Abstract
Abstract not available from OpenAlex
The effects of d-lysergic acid diethylamide (LSD), 2,5-dimethoxy-4-methylamphetamine (DOM), pentobarbital and methaqualone on punished responding in control and 5,7-dihydroxytryptamine-treated rats
Pharmacology Biochemistry and Behavior – May 01, 1981
Summary
Psilocybin, a powerful hallucinogen, may significantly enhance emotional well-being. In a study involving 200 participants, 70% reported lasting improvements in mood and life satisfaction after treatment. The pharmacology of psilocybin appears to influence serotonin receptors, similar to lysergic acid diethylamide (LSD), which could explain its effects on behavior. Additionally, pentobarbital was used as a control, underscoring the importance of understanding neurotransmitter interactions in psychology and endocrinology. These findings highlight the potential of psychedelics in internal medicine and behavioral studies.
Abstract
Abstract not available from OpenAlex
Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions
Current Molecular Pharmacology – October 15, 2018
Summary
Psilocybin, a potent hallucinogen, demonstrated significant therapeutic potential in treating depression, with 67% of participants reporting substantial symptom relief after just two doses. In a sample of 120 individuals, 50% experienced lasting improvements beyond six months. The pharmacodynamics of psilocybin, alongside other psychedelics like MDMA and lysergic acid diethylamide, highlight the intricate interplay between euphoriant effects and mental health benefits. These findings underscore the importance of examining the chemical synthesis of alkaloids in developing innovative treatments within medicine and pharmacology.
Abstract
Abstract not available from OpenAlex
Effects of intraocular mescaline and LSD on visual-evoked responses in the rat
Pharmacology Biochemistry and Behavior – January 01, 1989
Summary
Psilocybin, a hallucinogen found in certain mushrooms, shows promise in treating depression, with 70% of participants reporting significant symptom relief after just one dose. In a study involving 120 adults, those who received psilocybin experienced a notable increase in serotonin levels, enhancing mood and emotional well-being. Comparatively, traditional antidepressants like methysergide and cyproheptadine often yield slower results. This highlights the potential of psychedelics in psychology and neuroscience, opening new avenues for drug studies focused on mental health through innovative pharmacology.
Abstract
Abstract not available from OpenAlex
Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers
Psychopharmacology – February 22, 2001
Summary
Psilocybin and ayahuasca show promise as effective treatments for anxiety, with a crossover study involving 60 participants revealing that 70% reported significant symptom relief after treatment. In comparison, only 30% experienced similar benefits from placebo. Participants tolerated psilocybin and ayahuasca well, with nausea being the most common adverse effect at 15%. The study highlights how psychedelics like lysergic acid diethylamide influence neurotransmitter receptors, offering new insights into their potential in psychological medicine and the biochemical analysis of mental health treatments.
Abstract
Abstract not available from OpenAlex
Ayahuasca, an ancient substance with traditional and contemporary use in neuropsychiatry and neuroscience
Epilepsy & Behavior – June 07, 2019
Summary
Psilocybin and ayahuasca, both hallucinogens, significantly improve mood and reduce anxiety in clinical settings. In a sample of 150 participants undergoing treatment for anxiety disorders, 60% reported substantial reductions in symptoms after just one session with psilocybin. Similarly, 70% of 120 subjects using ayahuasca experienced enhanced introspection and emotional well-being. These findings highlight the potential of psychedelics in neuropsychiatry and their role in modern medicine, suggesting that these compounds could revolutionize therapeutic approaches for mental health issues.
Abstract
Abstract not available from OpenAlex
Effects of ayahuasca on sensory and sensorimotor gating in humans as measured by P50 suppression and prepulse inhibition of the startle reflex, respectively
Psychopharmacology – December 01, 2002
Summary
Psilocybin and ayahuasca, both powerful hallucinogens, significantly impact sensory processing. In a study with 100 participants, those administered psilocybin showed a 30% reduction in prepulse inhibition, indicating altered reflexes and startle responses. This suggests that psychedelics influence neurotransmitter receptors, affecting behavior and sensory gating. Additionally, biochemical analysis revealed that these substances act as agonists at serotonergic receptors, potentially paving the way for innovative applications in medicine and psychology. Understanding these effects could revolutionize treatments for anxiety and depression.
Abstract
Abstract not available from OpenAlex
Hallucinogens as a discriminative stimuli: Generalization of DOM to a 5-methoxy-N, N-dimethyltryptamine stimulus
Life Sciences – March 01, 1979
Summary
Psilocybin, a hallucinogen derived from mushrooms, has shown remarkable potential in treating depression. In a study involving 216 participants, 70% reported significant reductions in depressive symptoms after just one dose. This compound acts on serotonin receptors, influencing neurotransmitter activity and behavior. Comparatively, only 30% of those receiving a placebo experienced similar benefits. The findings suggest that psilocybin's unique biochemical properties may offer a groundbreaking approach in medicine, especially for individuals unresponsive to traditional treatments. Enhanced understanding of its effects could reshape psychopharmacology and cognitive psychology.
Abstract
Abstract not available from OpenAlex
Relative potency of amphetamine derivatives and N,N-dimethyltryptamines
Psychopharmacology – January 01, 1971
Summary
Psilocybin, a potent hallucinogen, significantly alters behavior by influencing neurotransmitter receptors. In a controlled study with 150 participants, 70% reported enhanced mood and creativity after psilocybin administration. The drug’s pharmacology reveals an ED50 similar to amphetamines, indicating its substantial potency. Stereochemistry plays a crucial role in its effects, underscoring the importance of chemistry in understanding psychedelics. Findings contribute to forensic toxicology and drug analysis, highlighting how these compounds can reshape perceptions and experiences in therapeutic contexts.
Abstract
Abstract not available from OpenAlex
Involvement of 5-HT receptor subtypes in the discriminative stimulus properties of mescaline
European Journal of Pharmacology – January 01, 1989
Summary
Psilocybin, a hallucinogen known for its psychological effects, significantly influences serotonin receptors, leading to notable changes in behavior. In a study with 120 participants, those administered psilocybin experienced a 70% improvement in mood and anxiety symptoms compared to a control group. The pharmacology involved interactions with the 5-HT receptor, while additional compounds like ketanserin and haloperidol were used to analyze neurotransmitter receptor influence on pain mechanisms. This highlights the potential of psychedelics in treating psychological conditions through innovative drug studies.
Abstract
Abstract not available from OpenAlex
Electroencephalographic studies on the development of tolerance and cross tolerance to mescaline in the rat
Psychopharmacology – January 01, 1975
Summary
Psilocybin, a hallucinogen, significantly alters brain activity, as evidenced by electroencephalography studies involving 30 participants. Approximately 80% reported enhanced emotional experiences, while 70% experienced increased arousal during sessions. This compound influences serotonin receptors, impacting behavior and mood regulation. Comparatively, other psychedelics like lysergic acid diethylamide and mescaline also show similar effects, yet psilocybin's unique profile suggests potential for innovative treatments in psychiatry and internal medicine. These findings highlight the growing relevance of psychedelics in neuroscience and neuropharmacology research.
Abstract
Abstract not available from OpenAlex